Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 + PM1009 in advanced or metastatic hepatocellular carcinoma (Ib/II)
CTR20243205Phase 2Active
- Sponsor
- Biotheus
- Start
- Dec 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pumitamig, PM1009 in hepatocellular carcinoma (HCC), sponsored by Biotheus. Started Dec 2024; status: active.
02
Drugs
pumitamigPM1009
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20243205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243205.